Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2014
Filed with the SEC on Feb 13, 2015 and accepted by EDGAR at Feb 13, 2015, 21:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-10-01 to 2014-12-31 | $144.6m | us-gaap:Revenues |
| Revenue | 12 months2014-01-01 to 2014-12-31 | $580.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-10-01 to 2014-12-31 | $11.3m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 12 months2014-01-01 to 2014-12-31 | $39.7m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2014-10-01 to 2014-12-31 | $201.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2014-01-01 to 2014-12-31 | $855.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2014-10-01 to 2014-12-31 | $78.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2014-01-01 to 2014-12-31 | $305.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-10-01 to 2014-12-31 | −$153.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2014-01-01 to 2014-12-31 | −$692.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2014-10-01 to 2014-12-31 | $2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2014-01-01 to 2014-12-31 | $7.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-10-01 to 2014-12-31 | −$176.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2014-01-01 to 2014-12-31 | −$738.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-10-01 to 2014-12-31 | −$0.74 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2014-01-01 to 2014-12-31 | −$3.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2014-01-01 to 2014-12-31 | −$3.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2014-01-01 to 2014-12-31 | 235,307,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2014-01-01 to 2014-12-31 | −$513.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2014-01-01 to 2014-12-31 | $51.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-12-31 | $625.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-12-31 | $1.55bn | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $2.33bn | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $368.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-12-31 | $1.24bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-12-31 | $1.08bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-15-000012. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.